267 related articles for article (PubMed ID: 21794954)
1. Phosphorylation in the amino terminus of tau prevents inhibition of anterograde axonal transport.
Kanaan NM; Morfini G; Pigino G; LaPointe NE; Andreadis A; Song Y; Leitman E; Binder LI; Brady ST
Neurobiol Aging; 2012 Apr; 33(4):826.e15-30. PubMed ID: 21794954
[TBL] [Abstract][Full Text] [Related]
2. Pathogenic forms of tau inhibit kinesin-dependent axonal transport through a mechanism involving activation of axonal phosphotransferases.
Kanaan NM; Morfini GA; LaPointe NE; Pigino GF; Patterson KR; Song Y; Andreadis A; Fu Y; Brady ST; Binder LI
J Neurosci; 2011 Jul; 31(27):9858-68. PubMed ID: 21734277
[TBL] [Abstract][Full Text] [Related]
3. Pseudophosphorylation of tau at S422 enhances SDS-stable dimer formation and impairs both anterograde and retrograde fast axonal transport.
Tiernan CT; Combs B; Cox K; Morfini G; Brady ST; Counts SE; Kanaan NM
Exp Neurol; 2016 Sep; 283(Pt A):318-29. PubMed ID: 27373205
[TBL] [Abstract][Full Text] [Related]
4. Pathological conformations involving the amino terminus of tau occur early in Alzheimer's disease and are differentially detected by monoclonal antibodies.
Combs B; Hamel C; Kanaan NM
Neurobiol Dis; 2016 Oct; 94():18-31. PubMed ID: 27260838
[TBL] [Abstract][Full Text] [Related]
5. The amino terminus of tau inhibits kinesin-dependent axonal transport: implications for filament toxicity.
LaPointe NE; Morfini G; Pigino G; Gaisina IN; Kozikowski AP; Binder LI; Brady ST
J Neurosci Res; 2009 Feb; 87(2):440-51. PubMed ID: 18798283
[TBL] [Abstract][Full Text] [Related]
6. Analysis of isoform-specific tau aggregates suggests a common toxic mechanism involving similar pathological conformations and axonal transport inhibition.
Cox K; Combs B; Abdelmesih B; Morfini G; Brady ST; Kanaan NM
Neurobiol Aging; 2016 Nov; 47():113-126. PubMed ID: 27574109
[TBL] [Abstract][Full Text] [Related]
7. Critical residues involved in tau binding to fyn: implications for tau phosphorylation in Alzheimer's disease.
Lau DH; Hogseth M; Phillips EC; O'Neill MJ; Pooler AM; Noble W; Hanger DP
Acta Neuropathol Commun; 2016 May; 4(1):49. PubMed ID: 27193083
[TBL] [Abstract][Full Text] [Related]
8. Frontotemporal Lobar Dementia Mutant Tau Impairs Axonal Transport through a Protein Phosphatase 1γ-Dependent Mechanism.
Combs B; Christensen KR; Richards C; Kneynsberg A; Mueller RL; Morris SL; Morfini GA; Brady ST; Kanaan NM
J Neurosci; 2021 Nov; 41(45):9431-9451. PubMed ID: 34607969
[TBL] [Abstract][Full Text] [Related]
9. Tau reduction prevents Aβ-induced axonal transport deficits by blocking activation of GSK3β.
Vossel KA; Xu JC; Fomenko V; Miyamoto T; Suberbielle E; Knox JA; Ho K; Kim DH; Yu GQ; Mucke L
J Cell Biol; 2015 May; 209(3):419-33. PubMed ID: 25963821
[TBL] [Abstract][Full Text] [Related]
10. miR-106b inhibits tau phosphorylation at Tyr18 by targeting Fyn in a model of Alzheimer's disease.
Liu W; Zhao J; Lu G
Biochem Biophys Res Commun; 2016 Sep; 478(2):852-7. PubMed ID: 27520374
[TBL] [Abstract][Full Text] [Related]
11. The protein phosphatase PP2A/Bα binds to the microtubule-associated proteins Tau and MAP2 at a motif also recognized by the kinase Fyn: implications for tauopathies.
Sontag JM; Nunbhakdi-Craig V; White CL; Halpain S; Sontag E
J Biol Chem; 2012 Apr; 287(18):14984-93. PubMed ID: 22403409
[TBL] [Abstract][Full Text] [Related]
12. Tau oligomers and tau toxicity in neurodegenerative disease.
Ward SM; Himmelstein DS; Lancia JK; Binder LI
Biochem Soc Trans; 2012 Aug; 40(4):667-71. PubMed ID: 22817713
[TBL] [Abstract][Full Text] [Related]
13. AlphaScreen HTS and live-cell bioluminescence resonance energy transfer (BRET) assays for identification of Tau-Fyn SH3 interaction inhibitors for Alzheimer disease.
Cochran JN; Diggs PV; Nebane NM; Rasmussen L; White EL; Bostwick R; Maddry JA; Suto MJ; Roberson ED
J Biomol Screen; 2014 Dec; 19(10):1338-49. PubMed ID: 25156556
[TBL] [Abstract][Full Text] [Related]
14. Phosphomimetics at Ser199/Ser202/Thr205 in Tau Impairs Axonal Transport in Rat Hippocampal Neurons.
Christensen KR; Combs B; Richards C; Grabinski T; Alhadidy MM; Kanaan NM
Mol Neurobiol; 2023 Jun; 60(6):3423-3438. PubMed ID: 36859689
[TBL] [Abstract][Full Text] [Related]
15. The microtubule-associated protein tau is also phosphorylated on tyrosine.
Lebouvier T; Scales TM; Williamson R; Noble W; Duyckaerts C; Hanger DP; Reynolds CH; Anderton BH; Derkinderen P
J Alzheimers Dis; 2009; 18(1):1-9. PubMed ID: 19542604
[TBL] [Abstract][Full Text] [Related]
16. Phosphorylation of tau by fyn: implications for Alzheimer's disease.
Lee G; Thangavel R; Sharma VM; Litersky JM; Bhaskar K; Fang SM; Do LH; Andreadis A; Van Hoesen G; Ksiezak-Reding H
J Neurosci; 2004 Mar; 24(9):2304-12. PubMed ID: 14999081
[TBL] [Abstract][Full Text] [Related]
17. Disease-related modifications in tau affect the interaction between Fyn and Tau.
Bhaskar K; Yen SH; Lee G
J Biol Chem; 2005 Oct; 280(42):35119-25. PubMed ID: 16115884
[TBL] [Abstract][Full Text] [Related]
18. Somatodendritic accumulation of Tau in Alzheimer's disease is promoted by Fyn-mediated local protein translation.
Li C; Götz J
EMBO J; 2017 Nov; 36(21):3120-3138. PubMed ID: 28864542
[TBL] [Abstract][Full Text] [Related]
19. Tyrosine 394 is phosphorylated in Alzheimer's paired helical filament tau and in fetal tau with c-Abl as the candidate tyrosine kinase.
Derkinderen P; Scales TM; Hanger DP; Leung KY; Byers HL; Ward MA; Lenz C; Price C; Bird IN; Perera T; Kellie S; Williamson R; Noble W; Van Etten RA; Leroy K; Brion JP; Reynolds CH; Anderton BH
J Neurosci; 2005 Jul; 25(28):6584-93. PubMed ID: 16014719
[TBL] [Abstract][Full Text] [Related]
20. Pyk2 is a Novel Tau Tyrosine Kinase that is Regulated by the Tyrosine Kinase Fyn.
Li C; Götz J
J Alzheimers Dis; 2018; 64(1):205-221. PubMed ID: 29782321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
